brexucabtagene autoleucel
Sales of the firm's TROP2-directed antibody-drug conjugate climbed 56 percent year over year thanks to increased demand among breast and bladder cancer patients.
Some patients whose CLL turned into lymphoma had durable responses on autologous cell therapies, according to a retrospective analysis featured at the ASH annual meeting.
Gilead Q1 Oncology Segment Sales Jump 59 Percent
Trodelvy sales increased 52 percent, Yescarta sales grew 70 percent, and Tecartus revenues increased 40 percent in Q1 2023 compared to the year-ago quarter.
NICE Backs Availability of Gilead's Yescarta, Tecartus Through Cancer Drugs Fund
The institute declined to recommend certain indications of the hematologic cancer drugs last year, but will collect additional data on their efficacy through the Cancer Drugs Fund.
Next-Gen Cell Therapies Bedeviled by Regulatory Murkiness on Product Characterization, Manufacturing
Premium
At a recent Friends of Cancer Research meeting, drugmakers and regulators said communication has improved on cell therapy development programs but acknowledged persistent challenges.